Annual CFF:
$2.45B+$1.81B(+282.69%)Summary
- As of today, PCVX annual cash from financing is $2.45 billion, with the most recent change of +$1.81 billion (+282.69%) on December 31, 2024.
- During the last 3 years, PCVX annual cash from financing has risen by +$2.43 billion (+13658.75%).
- PCVX annual cash from financing is now at all-time high.
Performance
PCVX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly CFF:
$2.52M+$1.76M(+231.75%)Summary
- As of today, PCVX quarterly cash from financing is $2.52 million, with the most recent change of +$1.76 million (+231.75%) on June 30, 2025.
- Over the past year, PCVX quarterly cash from financing has dropped by -$107.85 million (-97.72%).
- PCVX quarterly cash from financing is now -99.83% below its all-time high of $1.52 billion, reached on September 30, 2024.
Performance
PCVX Quarterly Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$1.52B-$107.85M(-6.61%)Summary
- As of today, PCVX TTM cash from financing is $1.52 billion, with the most recent change of -$107.85 million (-6.61%) on June 30, 2025.
- Over the past year, PCVX TTM cash from financing has increased by +$543.37 million (+55.45%).
- PCVX TTM cash from financing is now -37.79% below its all-time high of $2.45 billion, reached on December 31, 2024.
Performance
PCVX TTM Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
PCVX Cash From Financing Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1Y1 Year | +282.7% | -97.7% | +55.5% |
3Y3 Years | +10000.0% | -95.0% | +759.4% |
5Y5 Years | +5790.5% | -99.0% | +266.4% |
PCVX Cash From Financing Highs & Lows
PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
---|---|---|---|---|---|---|---|
3Y | 3-Year | at high | >+9999.0% | -99.8% | +231.8% | -37.8% | +612.9% |
5Y | 5-Year | at high | >+9999.0% | -99.8% | +6894.4% | -37.8% | >+9999.0% |
All-Time | All-Time | at high | >+9999.0% | -99.8% | +3370.1% | -37.8% | >+9999.0% |
PCVX Cash From Financing History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Jun 2025 | - | $2.52M(+231.8%) | $1.52B(-6.6%) |
Mar 2025 | - | $759.00K(-84.5%) | $1.63B(-33.4%) |
Dec 2024 | $2.45B(+282.7%) | $4.91M(-99.7%) | $2.45B(+0.1%) |
Sep 2024 | - | $1.52B(+1272.7%) | $2.45B(+149.7%) |
Jun 2024 | - | $110.37M(-86.5%) | $979.85M(-30.8%) |
Mar 2024 | - | $818.20M(>+9900.0%) | $1.42B(+121.4%) |
Dec 2023 | $639.81M(-25.7%) | $2.73M(-94.4%) | $639.81M(-50.5%) |
Sep 2023 | - | $48.55M(-91.1%) | $1.29B(+0.4%) |
Jun 2023 | - | $546.97M(+1216.0%) | $1.29B(+62.8%) |
Mar 2023 | - | $41.56M(-93.7%) | $792.09M(-8.1%) |
Dec 2022 | $861.55M | $656.63M(+1391.8%) | $861.55M(+303.2%) |
Sep 2022 | - | $44.02M(-11.8%) | $213.67M(+20.5%) |
Jun 2022 | - | $49.88M(-55.1%) | $177.25M(+38.1%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2022 | - | $111.02M(+1168.2%) | $128.33M(+621.1%) |
Dec 2021 | $17.80M(-95.3%) | $8.75M(+15.2%) | $17.80M(+85.4%) |
Sep 2021 | - | $7.60M(+694.9%) | $9.60M(+371.8%) |
Jun 2021 | - | $956.00K(+96.3%) | $2.03M(-99.2%) |
Mar 2021 | - | $487.00K(-12.3%) | $265.56M(-29.2%) |
Dec 2020 | $374.87M(+801.8%) | $555.00K(+1441.7%) | $374.87M(-9.8%) |
Sep 2020 | - | $36.00K(-100.0%) | $415.67M(-0.1%) |
Jun 2020 | - | $264.48M(+140.9%) | $416.00M(+174.7%) |
Mar 2020 | - | $109.80M(+165.5%) | $151.44M(+264.3%) |
Dec 2019 | $41.57M(-33.2%) | $41.35M(>+9900.0%) | $41.57M(>+9900.0%) |
Sep 2019 | - | $368.00K(+577.9%) | $215.00K(+240.5%) |
Jun 2019 | - | -$77.00K(-1.3%) | -$153.00K(-101.3%) |
Mar 2019 | - | -$76.00K | -$76.00K |
Dec 2018 | $62.19M | - | - |
FAQ
- What is Vaxcyte, Inc. annual cash from financing?
- What is the all-time high annual cash from financing for Vaxcyte, Inc.?
- What is Vaxcyte, Inc. annual cash from financing year-on-year change?
- What is Vaxcyte, Inc. quarterly cash from financing?
- What is the all-time high quarterly cash from financing for Vaxcyte, Inc.?
- What is Vaxcyte, Inc. quarterly cash from financing year-on-year change?
- What is Vaxcyte, Inc. TTM cash from financing?
- What is the all-time high TTM cash from financing for Vaxcyte, Inc.?
- What is Vaxcyte, Inc. TTM cash from financing year-on-year change?
What is Vaxcyte, Inc. annual cash from financing?
The current annual cash from financing of PCVX is $2.45B
What is the all-time high annual cash from financing for Vaxcyte, Inc.?
Vaxcyte, Inc. all-time high annual cash from financing is $2.45B
What is Vaxcyte, Inc. annual cash from financing year-on-year change?
Over the past year, PCVX annual cash from financing has changed by +$1.81B (+282.69%)
What is Vaxcyte, Inc. quarterly cash from financing?
The current quarterly cash from financing of PCVX is $2.52M
What is the all-time high quarterly cash from financing for Vaxcyte, Inc.?
Vaxcyte, Inc. all-time high quarterly cash from financing is $1.52B
What is Vaxcyte, Inc. quarterly cash from financing year-on-year change?
Over the past year, PCVX quarterly cash from financing has changed by -$107.85M (-97.72%)
What is Vaxcyte, Inc. TTM cash from financing?
The current TTM cash from financing of PCVX is $1.52B
What is the all-time high TTM cash from financing for Vaxcyte, Inc.?
Vaxcyte, Inc. all-time high TTM cash from financing is $2.45B
What is Vaxcyte, Inc. TTM cash from financing year-on-year change?
Over the past year, PCVX TTM cash from financing has changed by +$543.37M (+55.45%)